Europe Brain Cancer Diagnostics Market

Market Introduction

Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body.  Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

Thus, the increase in prevalence of brain cancer is expected to create a significant demand for brain cancer diagnostics in the coming years, which is further anticipated to drive the brain cancer diagnostics market.

Patients with cancer have been negatively impacted during the COVID-19 pandemic, as many of these individuals may be immunosuppressed and of older age. Additionally, cancer follow-up or imaging appointments have been delayed in many clinics around the world. Postponement of routine screening examinations will result in delays in new cancer diagnoses. Clinics are continuing to monitor and adapt their appointment schedules based on local outbreaks of COVID-19. Studies on COVID-19 in patients with cancer are limited, but consistently indicate that this population is at risk for more severe COVID-19 illness. Data from recent studies also suggest that pediatric patients with cancer have a lower risk of severe COVID-19 illness compared with adults. Certain features of SARS-CoV-2 infection detected by lung, brain, and gastrointestinal imaging may confound radiologists’ interpretation of cancer diagnosis, staging, and treatment response. Lastly, as clinics begin to reopen for routine appointments, protocols have been put in place to reduce SARS-CoV-2 exposure to patients during their visits. This review details different perspectives on the impact of the COVID-19 pandemic on patients with cancer and on cancer imaging.

Market Overview and Dynamics

The Brain cancer diagnostics market in Europe is expected to grow from US$ 207.5 million in 2021 to US$ 601.0 million by 2028; it is estimated to grow at a CAGR of 16.4% from 2021 to 2028. Artificial intelligence involves the use of powerful computers to perform tasks usually associated with human intelligence. A type of artificial intelligence called deep learning uses complex mathematical algorithms (sometimes called convolutional neural networks) to extract features from data and then "train" them. This training enables the algorithm to recognize patterns and perform tasks such as analysing images. To combine the powerful functions of the SRH imager with AI, the researchers began to perform algorithm training on the brain tumor tissue images produced by the SRH. The researchers pointed out that the ability of artificial intelligence technology and pathologists to verify each other highlights the need for pathologists to cooperate with artificial intelligence technology to interpret challenging cases and ensure the highest possible diagnostic accuracy. Both SRH and AI imaging are emerging technologies, so integrating them into healthcare will be challenging. AI technology enables surgeons to identify areas containing tumors or healthy tissue speedily and precisely. Thus, SRH?artificial intelligence is being increasingly used to enhance brain tumor diagnosis during surgery.    

Key Market Segments

In terms of diagnostic type, the imaging test segment accounted for the largest share of the Europe brain cancer diagnostics market in 2020. In terms of cancer type, the glioblastoma multiforme segment accounted for the largest share of the Europe brain cancer diagnostics market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Europe brain cancer diagnostics market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the brain cancer diagnostics market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Thermo Fisher Scientific Inc., Siemens Healthineers A, GE Healthcare, Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi, Ltd., and Neusoft Medical Systems.

Reasons to buy report

• To understand the Europe Brain cancer diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe Brain cancer diagnostics market
• Efficiently plan M&A and partnership deals in Europe Brain cancer diagnostics market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe Brain cancer diagnostics market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

Europe Brain Cancer Diagnostics Market Segmentation

By Diagnostic Type

• Imaging Test
  • MRI
  • CT Scan
  • PET
• Biopsy
• Molecular Testing
• Lumbar Puncture
• Others

By Cancer Type

• Glioblastoma Multiforme
• Astrocytomas
• Ependymomas
• Others

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Country

• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Companies Mentioned

1. Thermo Fisher Scientific Inc.
2. Siemens Healthineers A
3. GE Healthcare
4. Biocept, Inc.
5. Koninklijke Philips N.V
6. Canon Medical Systems
7. Hitachi, Ltd.
8. Neusoft Medical Systems

Europe Brain Cancer Diagnostics Market Strategic Insights

Europe Brain Cancer DiagnosticsMarket Report Highlights

Europe Brain Cancer Diagnostics Market Country and Regional Insights